SYSTEMATIC REVIEW ON EFFICACY OF THE F-18 FLUOROMISONIDAZOLE PET OR PET/CT
Author(s)
Yoo K
National Evidence-based Healthcare Collaborating Agency, Seoul, South Korea
OBJECTIVES: The purpose of this study was to evaluate whether F-18 fluoromisonidazole PET or PET/CT (FMISO) was safe and effective for malignant tumor patients and to determine a possibility of the introduction in Korea reimbursement regulation. METHODS: A systematic literature review was used to evaluate the safety and effectiveness for FMISO. The 27 articles were selected and two reviewers evaluated independently the quality of these selected articles using the Scottish Intercollegiate Guidelines Network (SIGN) tool. RESULTS: The correlation between tumor hypoxic imaging via FMISO and tumor imaging using existing imaging tests for diagnosing tumors in 14 articles was almost weak. By evaluating the hypoxic tumor lesions via FMISO, it was able to plan an intense radiotherapy that irradiate high dose in hypoxic area and to determine the therapeutic response and prognosis in 15 articles. CONCLUSIONS: The FMISO supplement the information of the heterogeneous tumor microenvironment as an add-on test and is a safe and effective test to determine the treatment direction through dose planning, prognosis, checking of therapeutic response for malignant cancer patients. Based on this evidence, FMISO will be introduced to the market within reimbursement regulation.
Conference/Value in Health Info
2015-11, ISPOR Europe 2015, Milan, Italy
Value in Health, Vol. 18, No. 7 (November 2015)
Code
PMD161
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes
Disease
Oncology